Sex: F
Vaccine: COVID19
Symptoms: ASIA syndrome, Autoantibody test, Basedow's disease, Blood thyroid stimulating hormone, Thyroid stimulating immunoglobulin
Clinical narrative: Graves' disease; Autoimmune Inflammatory Syndrome Induced by Unknown; This is a literature report for the following literature source(s): "Case Series Of New Onset Graves' Hyperthyroidism After Administration Of Sars-Cov. A 50-year-old female patient received BNT162b2 (BNT162B2), as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: BASEDOW'S DISEASE (medically significant), 1 month after the suspect product(s) administration, outcome "recovering", described as "Graves' disease"; ASIA SYNDROME (medically significant), outcome "recovering", described as "Autoimmune Inflammatory Syndrome Induced by Adjuvants (ASIA)". The patient underwent the following laboratory tests and procedures: Blood thyroid stimulating hormone: below 0.003, notes: 4 months later; Thyroid stimulating immunoglobulin: 3.99, notes: 4 months later; Thyroxine free: 4.1 ng/dL, notes: 4 months later; Autoantibody test: positive. Therapeutic measures were taken as a result of basedow's disease, asia syndrome. Additional information: The patient developed hyperthyroid symptoms one month following the first dose of the Pfizer vaccination. She responded well to methimazole 10 mg daily.  The patient didn't had a personal or family history of thyroid disease. Our case series adds to the growing evidence for SARS-CoV-2 vaccine-induced Graves' disease (GD), suggesting the incidence may be higher than initially thought and may occur after the 1st, 2nd or booster doses. One potential mechanism is the Autoimmune Inflammatory Syndrome Induced by Adjuvants (ASIA), which is likely triggered by the mRNA lipid nanoparticles present in the SARS-CoV-2 vaccine. Our patients all met criteria for ASIA with exposure to adjuvants, manifestations of autoimmune endocrine disorders, and positive autoantibodies. In our case series, patients had symptoms for weeks to months before their diagnosis of GD highlighting the importance of patient education regarding possible thyroid complications following vaccination to ensure prompt diagnosis and treatment.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.; Sender's Comments: Based on limited information in the case a possible causal association between the reported event Graves' disease, Autoimmune/inflammatory syndrome induced by adjuvants and the suspect drug   BNT162B2 cannot be excluded.  The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to RAs, Ethics Committees, and Investigators, as appropriate.,Linked Report(s) : US-PFIZER INC-PV202200099853 Same article and different patient /drug.;